Home / Business / Security shop Carbon Black files to go public

Security shop Carbon Black files to go public

Today Carbon Black filed to go public, publishing its S-1 document with a $100 million IPO figure as a placeholder.

The security-focused firm based in Massachusetts raised more than $190 million during its life as a private company, including a $54.5 million Series F in 2015 and a more modest $14 million Series F extension in 2016.

Today we’ll take a quick peek at the filing, which joins a number of other technology listings in an active IPO cycle. Carbon Black follows notable debuts such as Spotify and Dropbox, along with other, smaller debuts.

Into the numbers!

The big picture

Carbon Black is a big SaaS shop, something it makes plain in the early sections of its S-1 by noting that its revenue mix has increasingly skewed toward subscriptions. Indeed, according to Carbon Black, the firm’s “[r]ecurring revenue represented 77%, 83% and 88% of our total revenue in 2015, 2016 and 2017, respectively.”

That matters for investors as it helps them understand the company’s growth pace and its cash costs. SaaS companies are notorious for being predictable beasts, but also animals that have slipping growth rates in percentage terms and high upfront cash costs to generate their recurring top line.

Carbon Black is a great example of the model. The firm has grown its subscription (et al.) revenue line item greatly in recent years, but with the cost of rising deficits and high sales and marketing costs (as a percent of revenue and gross margin).

To save us both from reading a slower restatement of fact, here are the company’s guts and bolts, as we like to say:

Carbon Black’s revenue growth for calendar 2017 comes to 39.4 percent, down from 64.7 percent the year before.

Notably, the firm’s net loss fell during 2016, only to rise again in 2017. Companies often post rising deficits as they pursue growth. This is doubly true for SaaS companies willing to pay cash today for revenue growth tomorrow. In simpler terms, SaaS companies pay customer acquisition costs upfront but generate the benefits later on. And if a company is bolstering its sales costs during a growth cycle, the red ink can stretch quite far toward the horizon.

But there’s nuance to the firm’s losses, which we need to understand.

Losing money, and losing money

There’s a fun line item in the above called “[a]ccretion of preferred stock to redemption value,” which has risen and fallen over the past few years.1 This allowed Carbon Black to post a net loss decline in 2016, making its growth that year look particularly attractive. However, the return of that accretion cost pushed 2017’s net loss to a period-high.

Backing out that cost, and focusing on the company’s net loss result pre-accretion expenses, the firm’s net loss has instead posted steady growth as the firm has scaled.

Balling that up, from the above chart we can deduce that Carbon Black is growing at a goodly clip from a revenue base over the $100 million mark, with steadily rising operating losses (speaking loosely) and high sales and marketing costs.

What’s missing? A path to profitability, really. And that’s something the firm’s quarterly results don’t help with, as we will now see:

Let’s walk through that data set together. First, check the rightward progression of the firm’s net losses. Its losses go up with near-steady regularity. Next, execute the same exercise, but with the firm’s “Loss from operations” line. It’s a similar story.

So, as the firm grows, we can safely deduce that it’s an increasingly unprofitable affair. Mostly.

Turning to how the firm spends money, Carbon Black’s quarterly spend on sales and marketing, in percentage-of-revenue terms, was 65 percent in its most recent quarter. That was down from 67 in the year-ago quarter and as high as 71 percent in the first quarter of 2016. Since the first quarter of 2016 to the last of 2017, research and development costs have risen a single point; general and administrative costs fell from 22 percent of revenue to 14 percent. Those modest savings have pushed the firm’s percent-of-revenue losses into the low thirties.

Where they have stuck.

For Carbon Black, the question will be whether it can grow into profitability in the medium-term, or if its growth simply feels expensive compared to other companies; in a liquid market, every investment comes with opportunity costs.

At a minimum, and to Carbon Black’s credit, the security world doesn’t seem to be slowing much.

Odds & ends

Returning to the financials, how Carbon Black calculates its revenue retention is interesting, as it is more conservative than what we often find in similar IPO filings. In this case, Carbon Black doesn’t just compare revenue growth among a customer cohort over time from the clients it didn’t lose; instead, it calculates a more inclusive metric that includes customer churn.

But then Carbon Black goes a bit further, adding that it also “exclude[s] the impact of any add-on purchases from these customers during the measurement,” making its retention metric even stricter than we might have guessed. Regardless, we can read the results: “[Carbon Black’s] retention rate was 93% in 2015, 92% in 2016 and 93% in 2017.” That’s steady enough.

In closing, let’s talk bank accounts. How much cash does Carbon Black have on hand? The answer is not that much: $36.1 million. That’s a low-enough figure that we can presume that the firm is going public not because it simply wants to, but because it needs to raise new capital.

That’s no sin, mind, but let’s dismount with cash flow results to see if we are right. The firm’s free cash flow in 2016 came to negative $25.3 million. It fell, however, to just negative $13.8 million in 2017. Enough to run the company out of oxygen in just a few years. However, with, say, another $100 million in the bank, Carbon Black would have more than enough cash to scale — provided it doesn’t start to consume more cash to grow.

More when it prices — assuming this entire exercise isn’t just an attempt to get bought.

  1. Explained on page F-43 of the S-1, this cost is the “increase [in] the carrying values of the Series B, C, D, E, E-1 and F redeemable convertible preferred stock” over time. This accounting charge leads to “decreases to additional paid-in capital and an increase to accumulated deficit,” but has no bearing on operating results.

Check Also

Ezra raises $4M to diagnose cancer with MRIs, not painful biopsies

1 in 41 men will die of prostate cancer. But sticking a needle through your rectum into your prostate to screen for cancer brings along a ton of bacteria and terrible side effects like pain, infection, urinary trouble, and even erectile dysfunction. It turns out you can detect cancer with Magnetic Resonance Imaging…it’s just prohibitively expensive to do one-off MRIs and have radiologists analyze the scans. But by buying MRI slots in bulk and using artificial intelligence to scan them, a new medtech startup called Ezra wants to replace blood tests and biopsies with MRIs as the new standard of care. Today, Ezra launches v1 of its MRI prostate cancer screening subscription service in New York City. For $999 per year, patients get one MRI, access to medical staff and educational guides, and on-going support if the test finds they have cancer. For now, human radiologists still analyze the scans. However, Ezra is working to get FDA approval next year for its AI analysis that’s was initially found to be 90 percent as accurate as medical experts, and could turn Ezra into a lucrative and scalable medtech company. Comparing Radiologist and AI detection of cancer in MRI scans “One of the biggest problems in cancer is that there’s no accurate, fast, painless, way to scan for cancer anywhere in the body” says Ezra co-founder and CEO Emi Gal. He hopes that eventually, Ezra could offer full-body MRIs that make screening for all types of cancer easier to stomach so more cases can be caught early and more patients can survive. To build out its team and market to potential patients at risk for prostate cancer, Ezra is also announcing it’s raised a $4 million seed round led by Accomplice, the health-focused VC that funded PillPack before it was acquired by Amazon for nearly $1 billion. The firm was attracted by Ezra’s 50 percent gross margin on subscriptions that could get even higher at lower subscription prices once its AI is approved. “We’re not losing money every sale” Gal tells me. And while $999 might sound steep, he says a prostate MRI will cost you $1500 if you book it yourself. With 30 million men in the US alone at risk of prostate cancer, there’s urgent need for Ezra to fulfill its mission of “making MRI-based cancer screening affordable to everyone.” Ezra’s Super Hero Origin Gal has one of those startup founder super hero origin stories that gives him the grit necessary to see the problem through. “I developed hundreds of moles as a child that put me at very high risk of melanoma. Every year I’ve had to check for abnormalities and do a couple of biopsies” he candidly revealed. “I’ve been acutely aware of the importance of cancer screening since a young age.” Ezra co-founder and CeO Emi Gal After studying computer science and applied math in his home country of Romania, he built an adtech company at age 20 and sold it at 30. While working with terminally ill cancer patient charity Hospices Of Hope, he seized on the need for better cancer screenings and began his research about different methods. “The more scientists I spoke to, the more convinced I became to build a new screening modality” he recalls. Typically, prostate cancer screenings involve a blood test for prostate-specific antigen, with an needle-through-the-rectum biopsy done if PSA levels are elevated. But PSA levels can be inaccurate, triggering painful and unnecessary biopsies. Gal discovered a recent study by a leading urologist that looked at 500 patients with some diagnosed the traditional way, and some with an MRI that when cancer is detected is then used to guide a biopsy. The latter method identified 18 percent more cases of cancer while reducing unnecessary biopsies and the associated side effects by 27 percent, the study found. MRIs could work. So Ezra conducted its own investigation to see if AI could perform as well as a radiologist. It had three experts mark up a data set from the National Institute Of Health and trained its AI on the data set through the work of Gal’s co-founder Diego Canto, a PhD in deep learning applied to MRI. They found the AI was 90 accurate at agreeing with the experts on a new data set. Now an FDA regulatory expert on the team is trying to get the AI approved to assist radiologists to lower Ezra’s labor costs. Magnetic Resonance Innovation Rather than wait around, Ezra has partnered with the leading MRI facility network RadNet. It buys MRI time slots in bulk for a cheaper rate, starting with a location in Lenox Hill, Manhattan. Next year it will expand to more RadNet locations beyond New York City. If the AI gets approval, there’ll still be human medical experts involved. The AI eliminates the grunt work of doing measurements and annotating MRI scans so the human can focus on just making the cancer/not cancer call. And if the diagnosis sadly is positive, “What we don’t want to do is just drop a report on people that says ‘you likely have cancer’. We want to help with the treatment process and recommend the best urologists” Gal tells me. A study found AI to agree with medical experts on prostate cancer detection 90 percent of the time The combination of hard technology and the booming direct-to-consumer industry drew the $4 million round that also includes Founders Future, Credo Ventures, Seedcamp, Esther Dyson and a number of startup founders and angel investors like SoundCloud co-founder Alex Ljung. They see Ezra as differentiated from expensive overall health screening services like the $25,000 Human Longevity Inc. “Ezra’s uniqueness stands as much in the company’s investigational AI technology as it does in its innovative consumer-centric cancer screening model” says John Crues, M.D. RadNet’s Medical Director. But the biggest threat to Ezra is insurance. If it can’t convince insurers that MRIs that are expensive up front but could be more accurate with fewer complications are more capital efficient long-term than the biopsy status quo, it may have a very tough time getting people to pay $1000 out of pocket. It will also have to find the right balance of margins and affordability that insurers will tolerate. “We want to focus on building a data set that proves [MRIs] are more accurate, less painful, and faster than that the standard of care” Gal concludes. If it can institute MRIs as the new standard for prostate screenings, Ezra will be on its way to offering a single painless test that could spot cancer early enough that it can be beaten. Cancer will kill 9.6 million people this year. It doesn’t have to be that way.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Disclaimer: Trading in bitcoins or other digital currencies carries a high level of risk and can result in the total loss of the invested capital. theonlinetech.org does not provide investment advice, but only reflects its own opinion. Please ensure that if you trade or invest in bitcoins or other digital currencies (for example, investing in cloud mining services) you fully understand the risks involved! Please also note that some external links are affiliate links.